Bayer Plans to Take Over All Remaining Sites in Germany, Following Frankfurt Operations
In a significant move, Bayer, the German multinational pharmaceutical and life sciences company, has pledged to retain key production and research sites in Germany beyond 2030. This commitment is part of a broader agreement with local stakeholders, aimed at ensuring long-term investment and site retention.
The announcement was made by Bayer's CEO, Bill Anderson, who highlighted Germany's importance to the company. In a joint statement with employees, the Bayer board guaranteed the retention of all other sites in Germany until 2030. However, the exact terms of this agreement and the affected sites are yet to be disclosed in official Bayer announcements or reliable news sources.
The decision to exit the Frankfurt site by 2030, which will result in the loss of around 500 jobs, has been justified due to high energy costs in Germany. To make this transition socially acceptable, the company and employees have agreed on measures such as protecting current working conditions, attractive severance packages, and support for employees in transferring jobs from Frankfurt to Monheim.
In a show of solidarity, works council chair Heike Hausfeld and Francesco Grioli of the IGBCE union have commented on the situation. They have confirmed that a collective protection against dismissal for a portion of employees from 2027 will be followed by "individual protection for all employees" in Germany.
Moreover, the agreement provides fair, secure, and sustainable prospects for everyone, with employees whose position is abolished in the company as of January 2027 and who do not leave with a severance package after a six-month consideration period being granted a protected phase for career transition. During this period, dismissal is excluded based on the duration of their employment.
Bayer has also promised job security for those employees who may be moving to other sites, with measures in place to ensure a smooth transition. The company is committed to ensuring that the exit from Frankfurt is carried out in a way that is socially acceptable and minimises disruption for its employees.
As Bayer continues to navigate this transition, it remains dedicated to its commitment to Germany and its workforce, aiming to maintain a strong presence in the country for years to come. For the latest updates on Bayer's site retention policies beyond 2030, it is recommended to consult Bayer's official press releases, corporate responsibility reports, or trusted business news outlets focusing on the chemical and pharmaceutical industry in Germany.
In light of their commitment to Germany, Bayer has agreed with stakeholders on a broader plan to ensure long-term investment and site retention. This includes a strengthened community policy, one aspect of which is providing vocational training for employees to become qualified for available positions within the company as others are phased out, ensuring financial security and continued employment. Additionally, the company is working closely with the industry and various business entities to explore opportunities for vocational training, possibly expanding into new sectors to upskill the workforce.
